Jedličková L, Dvorak J, Hrachovinova I, Ulrychová L, Kasný M, Mikes L. A novel Kunitz protein with proposed dual function from Eudiplozoon nipponicum (Monogenea) impairs haemostasis and action of complement in vitro. Int J Parasitol. 2019;: pubmed publisher

Portelli M, Siedlinski M, Stewart C, Postma D, Nieuwenhuis M, Vonk J, et al. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J. 2014;28:923-34 pubmed publisher

Willrich M, Baudhuin L. PCSK9 and the road less traveled: how an unconventional approach led to a major discovery. Clin Chem. 2013;59:1283-4 pubmed

Zorina V, Zorin N. [Protein components of innate immunity in protection from pathogenic invasion (literature review)]. Zh Mikrobiol Epidemiol Immunobiol. 2013;:111-7 pubmed

Belousov I, Chernogubova E, Kogan M. [The role of endothelial dysfunction in the pathogenesis of non-inflammatory form of chronic abacterial prostatitis]. Urologiia. 2013;:39-42 pubmed

Schmitt M, Renne T, Scorilas A. The kallikreins: old proteases with new clinical potentials. Thromb Haemost. 2013;110:396-8 pubmed publisher

Björkqvist J, Jämsä A, Renne T. Plasma kallikrein: the bradykinin-producing enzyme. Thromb Haemost. 2013;110:399-407 pubmed publisher

Balaban N, Danilova I, Shamsutdinov T, Mardanova A, Cheremin A, Rudenskaia G, et al. [Properties of Bacillus pumilus subtilisin like proteinase secreted from recombinant strain on different growth stages]. Bioorg Khim. 2013;39:46-54 pubmed

Sheffield C, Crippen T, Poole T, Beier R. Destruction of single-species biofilms of Escherichia coli or Klebsiella pneumoniae subsp. pneumoniae by dextranase, lactoferrin, and lysozyme. Int Microbiol. 2012;15:185-9 pubmed

Lamy S, Wilmart J, Hein T, Scheiden R, Capesius C. [Prostate cancer in Luxembourg from 1982 to 2006. Incidence and mortality. Survival of a hospital cohort]. Bull Soc Sci Med Grand Duche Luxemb. 2013;:6-19 pubmed

Zaorsky N, Raj G, Trabulsi E, Lin J, Den R. The dilemma of a rising prostate-specific antigen level after local therapy: what are our options?. Semin Oncol. 2013;40:322-36 pubmed publisher

Chen Q, Lee T, Kumar A, Min J, Choi J. Analysis of nanoscale protein film consisting of lactoferrin/11-MUA bilayers for bioelectronic device. J Biomed Nanotechnol. 2013;9:849-55 pubmed

Yeap S, Omar A, Ho W, Beh B, Ali A, Alitheen N. Rhaphidophora korthalsii modulates peripheral blood natural killer cell proliferation, cytokine secretion and cytotoxicity. BMC Complement Altern Med. 2013;13:145 pubmed publisher

Yang W, Han W, Ye S, Liu D, Wu J, Liu H, et al. Fibroblast activation protein-? promotes ovarian cancer cell proliferation and invasion via extracellular and intracellular signaling mechanisms. Exp Mol Pathol. 2013;95:105-10 pubmed publisher

Tietge U, Groen A. Role the TICE?: advancing the concept of transintestinal cholesterol excretion. Arterioscler Thromb Vasc Biol. 2013;33:1452-3 pubmed publisher

Suzuki M, Yamanoi A, Machino Y, Kobayashi E, Fukuchi K, Tsukimoto M, et al. Cleavage of the interchain disulfide bonds in rituximab increases its affinity for FcγRIIIA. Biochem Biophys Res Commun. 2013;436:519-24 pubmed publisher

Takadanohara H, Catanzaro R, Chui D, He F, Yadav H, Ganguli A, et al. Beneficial effect of a symbiotic preparation with S. boulardii lysate in mild stress-induced gut hyper-permeability. Acta Biomed. 2012;83:208-16 pubmed

Camaschella C. Treating iron overload. N Engl J Med. 2013;368:2325-7 pubmed publisher

Pereira M, Byrne B, Nguyen T, Lewis D, Atwill E. The occurrence of subtilase-cytotoxin-encoding genes in environmental Escherichia coli isolated from a Northern California estuary. Can J Microbiol. 2013;59:437-41 pubmed publisher

Hogendorf A, Stańczyk Przyłuska A, Sieniwicz Luzeńczyk K, Wiszniewska M, Arendarczyk J, Banasik M, et al. Is there any association between secretory IgA and lactoferrin concentration in mature human milk and food allergy in breastfed children. Med Wieku Rozwoj. 2013;17:47-52 pubmed

Stolp J, Marino E, Batten M, Sierro F, Cox S, Grey S, et al. Intrinsic molecular factors cause aberrant expansion of the splenic marginal zone B cell population in nonobese diabetic mice. J Immunol. 2013;191:97-109 pubmed publisher

Bubber P, Chauhan A, Sharma A, Bubber N, Bansal D. Effect of thyroxine on fibrinolytic system in rat. Indian J Physiol Pharmacol. 2012;56:267-72 pubmed

Gerhardt E, Masso M, Paton A, Paton J, Zotta E, Ibarra C. Inhibition of water absorption and selective damage to human colonic mucosa are induced by subtilase cytotoxin produced by Escherichia coli O113:H21. Infect Immun. 2013;81:2931-7 pubmed publisher

Endow J, Inoue K. Stable complex formation of thylakoidal processing peptidase and PGRL1. FEBS Lett. 2013;587:2226-31 pubmed publisher

Diener H, Foerch C, Riess H, Rother J, Schroth G, Weber R. Treatment of acute ischaemic stroke with thrombolysis or thrombectomy in patients receiving anti-thrombotic treatment. Lancet Neurol. 2013;12:677-88 pubmed publisher

Martin A, Lord S, Verry H, Stockler M, Emery J. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis. Med J Aust. 2013;198:546-50 pubmed

Rychetnik L, Carter S, Barratt A, Irwig L. Expanding the evidence on cancer screening: the value of scientific, social and ethical perspectives. Med J Aust. 2013;198:536-9 pubmed

Hugosson J, Carlsson S. The dilemmas of prostate cancer screening. Med J Aust. 2013;198:528-9 pubmed

Del Mar C, Glasziou P, Hirst G, Wright R, Hoffmann T. Should we screen for prostate cancer? A re-examination of the evidence. Med J Aust. 2013;198:525-7 pubmed

Matsuoka H, Kurata T, Okamoto I, Kaneda H, Tanaka K, Nakagawa K. Clinical response to crizotinib retreatment after acquisition of drug resistance. J Clin Oncol. 2013;31:e322-3 pubmed publisher

Ohnishi Y, Yamada T, Kurihara K, Tanaka I, Sakiyama F, Masaki T, et al. Neutron and X-ray crystallographic analysis of Achromobacter protease I at pD 8.0: protonation states and hydration structure in the free-form. Biochim Biophys Acta. 2013;1834:1642-7 pubmed publisher

Ero M, Ng C, Mihailovski T, Harvey N, Lewis B. A pilot study on the serum pharmacokinetics of nattokinase in humans following a single, oral, daily dose. Altern Ther Health Med. 2013;19:16-9 pubmed

Xu Z, Chen X, Peng C, Liu E, Li Y, Li C, et al. The expression and clinical significance of Omi/Htra2 in hepatocellular carcinoma. Hepatogastroenterology. 2013;60:6-13 pubmed

Feener E, Zhou Q, Fickweiler W. Role of plasma kallikrein in diabetes and metabolism. Thromb Haemost. 2013;110:434-41 pubmed publisher

Nagashima T, Li Q, Clementi C, Lydon J, DeMayo F, Matzuk M. BMPR2 is required for postimplantation uterine function and pregnancy maintenance. J Clin Invest. 2013;123:2539-50 pubmed publisher

Akhatib B, Onnerfjord P, Gawri R, Ouellet J, Jarzem P, Heinegard D, et al. Chondroadherin fragmentation mediated by the protease HTRA1 distinguishes human intervertebral disc degeneration from normal aging. J Biol Chem. 2013;288:19280-7 pubmed publisher

Friis S, Uzzun Sales K, Godiksen S, Peters D, Lin C, Vogel L, et al. A matriptase-prostasin reciprocal zymogen activation complex with unique features: prostasin as a non-enzymatic co-factor for matriptase activation. J Biol Chem. 2013;288:19028-39 pubmed publisher

Hirayama S, Miida T. [Genetic predisposition to dyslipidemia]. Rinsho Byori. 2013;61:159-66 pubmed

Baeriswyl V, Calzavarini S, Gerschheimer C, Diderich P, Angelillo Scherrer A, Heinis C. Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy. J Med Chem. 2013;56:3742-6 pubmed publisher

Pathak M, Wong S, Dreveny I, Emsley J. Structure of plasma and tissue kallikreins. Thromb Haemost. 2013;110:423-33 pubmed publisher

Millers E, Johnson L, Birrell G, Masci P, Lavin M, de Jersey J, et al. The structure of human microplasmin in complex with textilinin-1, an aprotinin-like inhibitor from the Australian brown snake. PLoS ONE. 2013;8:e54104 pubmed publisher

Liu J, Clermont A, Gao B, Feener E. Intraocular hemorrhage causes retinal vascular dysfunction via plasma kallikrein. Invest Ophthalmol Vis Sci. 2013;54:1086-94 pubmed publisher

Iarovaia G, Neshkova E, Blokhina T, Kochergin S, Vorob eva I, Gigineishvili D. [Kallikrein-kinin system as a target for diabetic retinopathy treatment]. Vestn Oftalmol. 2012;128:78-81 pubmed

Renne T, Gruber A. Plasma kallikrein: novel functions for an old protease. Thromb Haemost. 2012;107:1012-3 pubmed publisher

Chen S, Morales Sanfrutos J, Angelini A, Cutting B, Heinis C. Structurally diverse cyclisation linkers impose different backbone conformations in bicyclic peptides. Chembiochem. 2012;13:1032-8 pubmed publisher

Baeriswyl V, Rapley H, Pollaro L, Stace C, Teufel D, Walker E, et al. Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteases. ChemMedChem. 2012;7:1173-6 pubmed publisher

Bird J, Smith P, Wang X, Schumacher W, Barbera F, Revelli J, et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost. 2012;107:1141-50 pubmed publisher

Kolte D, Bryant J, Gibson G, Wang J, Shariat Madar Z. PF-04886847 (an inhibitor of plasma kallikrein) attenuates inflammatory mediators and activation of blood coagulation in rat model of lipopolysaccharide (LPS)-induced sepsis. Cardiovasc Hematol Agents Med Chem. 2012;10:154-66 pubmed

Saito A. Diversity of human plasma protein C inhibitor. Thromb Res. 2012;130:661-6 pubmed publisher

Heinis C. Bicyclic peptide antagonists derived from genetically encoded combinatorial libraries. Chimia (Aarau). 2011;65:677-9 pubmed

Earl S, Richards R, Johnson L, Flight S, Anderson S, Liao A, et al. Identification and characterisation of Kunitz-type plasma kallikrein inhibitors unique to Oxyuranus sp. snake venoms. Biochimie. 2012;94:365-73 pubmed publisher

Clermont A, Chilcote T, Kita T, Liu J, Riva P, Sinha S, et al. Plasma kallikrein mediates retinal vascular dysfunction and induces retinal thickening in diabetic rats. Diabetes. 2011;60:1590-8 pubmed publisher

Liu J, Gao B, Clermont A, Blair P, Chilcote T, Sinha S, et al. Hyperglycemia-induced cerebral hematoma expansion is mediated by plasma kallikrein. Nat Med. 2011;17:206-10 pubmed publisher

Austin H, De Staercke C, Lally C, Bezemer I, Rosendaal F, Hooper W. New gene variants associated with venous thrombosis: a replication study in White and Black Americans. J Thromb Haemost. 2011;9:489-95 pubmed publisher

Kolte D, Bryant J, Holsworth D, Wang J, Akbari P, Gibson G, et al. Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor. Br J Pharmacol. 2011;162:1639-49 pubmed publisher

Banerji A. Current treatment of hereditary angioedema: An update on clinical studies. Allergy Asthma Proc. 2010;31:398-406 pubmed publisher

López Lera A, Favier B, de la Cruz R, Garrido S, Drouet C, Lopez Trascasa M. A new case of homozygous C1-inhibitor deficiency suggests a role for Arg378 in the control of kinin pathway activation. J Allergy Clin Immunol. 2010;126:1307-10.e3 pubmed publisher

Stolz L, Horn P. Ecallantide: a plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema. Drugs Today (Barc). 2010;46:547-55 pubmed publisher

Dellalibera Joviliano R, Joviliano E, Evora P. Determination of kininogens levels and kallikrein/kininase II activities in patients with thromboangiitis obliterans. Scand J Immunol. 2010;72:128-33 pubmed publisher

Feener E. Plasma kallikrein and diabetic macular edema. Curr Diab Rep. 2010;10:270-5 pubmed publisher

Dellalibera Joviliano R, Reis M, Donadi E. The kinin system in patients with systemic lupus erythematosus exhibiting mucocutaneous lesions: a clinical study. Scand J Immunol. 2010;71:292-7 pubmed publisher

Kaplan A, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:193-204 pubmed publisher

Stoop A, Joshi R, Eggers C, Craik C. Analysis of an engineered plasma kallikrein inhibitor and its effect on contact activation. Biol Chem. 2010;391:425-33 pubmed publisher

Almeida S, Barros C, Moraes M, Russo F, Haro A, Rosa T, et al. Plasma Kallikrein and Angiotensin I-converting enzyme N- and C-terminal domain activities are modulated by the insertion/deletion polymorphism. Neuropeptides. 2010;44:139-43 pubmed publisher

McRae B, Kurachi K, Heimark R, Fujikawa K, Davie E, Powers J. Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates. Biochemistry. 1981;20:7196-206 pubmed

Heimark R, Davie E. Bovine and human plasma prekallikrein. Methods Enzymol. 1981;80 Pt C:157-72 pubmed

Silverberg M, Kaplan A. Prekallikrein. Methods Enzymol. 1988;163:85-95 pubmed

Seidah N, Ladenheim R, Mbikay M, Hamelin J, Lutfalla G, Rougeon F, et al. The cDNA structure of rat plasma kallikrein. DNA. 1989;8:563-74 pubmed

Tsuda Y, Teno N, Okada Y, Wanaka K, Bohgaki M, Hijikata Okunomiya A, et al. Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein. Chem Pharm Bull (Tokyo). 1989;37:3108-11 pubmed